KB-1166

10F9G2-hIgG1

Background

10F9G2 monoclonal antibody can bind to mouse PD-L1 (programmed death ligand 1). Programmed cell death 1 ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1), is encoded by the CD274 gene. Recent years, a total of 5 PD-1/PD-L1 antibody drugs have been approved, including 2 PD-1 inhibitors and 3 PD-L1 inhibitors, with indications involving non-small cell lung cancer, gastric cancer, melanoma kidney cancer, etc., and new indications will be approved one after another. 10F9G2 antibodies have been shown to block the interaction between PD-L1 and PD-1 and PD-L1 and B7-1 (CD80), promising for cancer treatment.

Specifications

Catalog Number:
KB-1166
Cell Line Name:
10F9G2-hIgG1
Price:
0
Host Cell Line:
EXPI-CHO
Target:
Mouse-PDL1
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Bylicki, Olivier; Paleiron, Nicolas; Rousseau-Bussac, Gaelle; Chouaid, Christos (2018). New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab. OncoTargets and Therapy, Volume 11(), 4051–4064. doi:10.2147/OTT.S154606. 2.Basile, Debora; Pelizzari, Giacomo; Vitale, Maria Grazia; Lisanti, Camilla; Cinausero, Marika; Iacono, Donatella; Puglisi, Fabio (2018). Atezolizumab for the treatment of Breast Cancer. Expert Opinion on Biological Therapy, (), 14712598.2018.1469619–. doi:10.1080/14712598.2018.1469619. 3.Siyu Wang;Yue Song;Kunxia Cao;Lingxiao Zhang;Xuedong Fang;Fangfang Chen;Shouhua Feng;Fei Yan; (2021). Photothermal therapy mediated by gold nanocages composed of anti-PDL1 and galunisertib for improved synergistic immunotherapy in colorectal cancer . Acta Biomaterialia, (), –. doi:10.1016/j.actbio.2021.07.051
Please enable JavaScript in your browser to complete this form.